Long-term outcomes data will be collected to analyze aprevo devices — Carlsmed’s patient-specific interbody for the treatment of adult spinal deformity — in improving outcomes and reducing complications.
In December, the FDA granted aprevo its breakthrough device designation, which expedites the time taken to reach clinical trials.
“As breakthrough technology, aprevo has been determined by FDA to provide for a more effective treatment than the current standard of care,” Carlsmed CEO Mike Cordonnier said in a July 28 news release. “We are committed to partnering with thought leaders in the mission to collect data and improve outcomes for patients with debilitating spine disorders.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
